Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

CRLF2 (Cytokine Receptor Like Factor 2)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

FusionPlex™ Pan-Heme panel

FusionPlex™ Pan-Heme panel

›

CRLF2 rearrangement + JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	CRLF2 rearrangement + JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
CRLF2 rearrangement	Acute Lymphocytic Leukemia	CRLF2 rearrangement	Acute Lymphocytic Leukemia	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2
CRLF2 rearrangement	Acute Lymphocytic Leukemia	CRLF2 rearrangement	Acute Lymphocytic Leukemia	T-lymphocyte cell therapy + ruxolitinib Sensitive: C2 – Inclusion Criteria T-lymphocyte cell therapy + ruxolitinib Sensitive : C2	T-lymphocyte cell therapy + ruxolitinib Sensitive: C2 – Inclusion Criteria T-lymphocyte cell therapy + ruxolitinib Sensitive : C2
CRLF2 rearrangement	Acute Lymphocytic Leukemia	CRLF2 rearrangement	Acute Lymphocytic Leukemia	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
CRLF2 overexpression	B Acute Lymphoblastic Leukemia	CRLF2 overexpression	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
CRLF2 overexpression	B Acute Lymphoblastic Leukemia	CRLF2 overexpression	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
CRLF2 overexpression	B Acute Lymphoblastic Leukemia	CRLF2 overexpression	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C3 – Early Trials blinatumomab + inotuzumab ozogamicin Sensitive : C3	blinatumomab + inotuzumab ozogamicin Sensitive: C3 – Early Trials blinatumomab + inotuzumab ozogamicin Sensitive : C3
P2RY8-CRLF2 fusion	Acute Myelogenous Leukemia	P2RY8-CRLF2 fusion	Acute Myelogenous Leukemia	ipilimumab Sensitive: C4 – Case Studies ipilimumab Sensitive : C4	ipilimumab Sensitive: C4 – Case Studies ipilimumab Sensitive : C4
P2RY8-CRLF2 fusion	B Acute Lymphoblastic Leukemia	P2RY8-CRLF2 fusion	B Acute Lymphoblastic Leukemia	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
IGH-CRLF2 fusion + JAK2 R867Q	Childhood B Acute Lymphoblastic Leukemia	IGH-CRLF2 fusion + JAK2 R867Q	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D
IGH-CRLF2 fusion + JAK2 R683G	Acute Lymphocytic Leukemia	IGH-CRLF2 fusion + JAK2 R683G	Acute Lymphocytic Leukemia	nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical nanoparticle albumin-bound rapamycin Sensitive : D	nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical nanoparticle albumin-bound rapamycin Sensitive : D
IGH-CRLF2 fusion	Childhood B Acute Lymphoblastic Leukemia	IGH-CRLF2 fusion	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D